IGC Pharma has entered a master co-operation agreement with the University of Los Andes in Colombia to develop and adopt generative artificial intelligence (AI) solutions to detect, develop and trial new drugs.
The company will leverage generative AI to streamline the efficiency of its clinical trials, improve early Alzheimer’s disease detection approaches and enhance drug interaction assessments.
The company’s drug asset, IGC-AD1, is being analysed in Phase II trials to treat agitation associated with Alzheimer’s symptoms.
IGC is advancing four more assets: TGR-63, LMP, IGC-1C and IGC-M3, to the clinic for Alzheimer’s indication.
The company plans to use AI algorithms in trials to boost efficiency in study progression, cost-cutting and data evaluations.
It also anticipates reducing the possibility of false negatives in early Alzheimer’s detection and boosting the chances of successful treatment by merging AI algorithms into the evaluation process.
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
IGC intends to incorporate AI algorithms into drug interaction analysis to design new methodologies for physicians. This approach could aid in rapidly assessing interactions between formulations of Alzheimer’s treatments.
IGC Pharma CEO Ram Mukunda stated: “We are very pleased to be partnering with the University of Los Andes to further our AI initiatives through the development and adoption of AI algorithms that have the potential to significantly enhance the treatment of Alzheimer’s disease and other chronic illnesses.
“As we execute our strategic initiatives and position IGC Pharma at the forefront of AI adoption, we expect to gain a distinct competitive advantage as we streamline clinical trial efficiencies, enhance early detection of Alzheimer’s, improve methodologies for the analysis of drug interaction and improve the treatment experience for patients, should our AI algorithms prove successful.”
